Background. Over the past decade new insights in our understanding of coagulation have
identified the prominent role of tissue factor. The brain is rich in tissue factor, and injury to the …

The objective was to systematically review the medical literature and comprehensively
summarize clinical research performed on biomarkers for pediatric traumatic brain injury …

Background: The incidence and risk factors for traumatic brain injury (TBI)-associated
coagulopathy after severe TBI (sTBI) and the effect of this complication on outcomes have …

Background Worldwide, over 10 million people are killed or hospitalized because of
traumatic brain injury each year. About 90% of deaths occur in low-and middle-income …

BACKGROUND: Tranexamic acid (TXA) has been shown to reduce blood loss in surgical
patients and the risk of death in patients with traumatic bleeding, with no apparent increase …

Objective The antifibrinolytic agent tranexamic acid (TXA) has demonstrated clinical benefit
in trauma patients with severe bleeding, but its effectiveness in patients with traumatic brain …

BACKGROUND Tranexamic acid safely reduces mortality in traumatic extracranial bleeding.
Intracranial bleeding is common after traumatic brain injury and can cause brain herniation …

Objective To assess the effect of tranexamic acid (which reduces bleeding in surgical
patients and reduces mortality due to bleeding in trauma patients) on intracranial …

As of August 2007, 96 900 people are awaiting organ transplantation in the United States,
while only 28 930 transplants were performed in 2006. With such a large gap between …

Traumatic brain injury (TBI) is one of the leading causes of morbidity, disability and mortality
across all age groups globally. Currently, only palliative treatments exist, but these are …